1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cardiotoxicity Screening Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cardiotoxicity Screening Market Revenue and Volume Forecast, by Assay/Test Type
8.1.1. hERG (Kv11.1) Binding and Patch-Clamp Assays
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Automated Patch Clamp (APC)
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Multi-Electrode Array (MEA) with iPSC-Cardiomyocytes
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Calcium-Flux and Optical Electrophysiology Assays
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. In vivo Telemetry/Conscious ECG Studies (rodent, dog, non-rodent)
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. In Silico Predictive Modeling and QSAR/CiPA Workflows
8.1.6.1. Market Revenue and Volume Forecast
9.1. Cardiotoxicity Screening Market Revenue and Volume Forecast, by Modality/Approach
9.1.1. In Vitro (cell and tissue-based)
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. In Vivo (animal telemetry, ECG)
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. In Silico/Computational (simulation, PBPK-QT models)
9.1.3.1. Market Revenue and Volume Forecast
10.1. Cardiotoxicity Screening Market Revenue and Volume Forecast, by Product and Service Type
10.1.1. Assay Kits, Reagents and Ready-to-use Cells (iPSC-cardiomyocytes, dyes, media)
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Instrumentation and Platforms (MEA systems, APC rigs, patch amplifiers)
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Contract Testing Services/CRO Screening Programs
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Software and Predictive Analytics (QTc algorithms, pro-arrhythmia AI)
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Consulting, Validation, and Regulatory Support
10.1.5.1. Market Revenue and Volume Forecast
11.1. Cardiotoxicity Screening Market Revenue and Volume Forecast, by End User
11.1.1. Pharmaceutical and Biotechnology Companies (in-house screening)
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. CROs/Safety and Toxicology Service Providers
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Academic and Research Institutes
11.1.3.1. Market Revenue and Volume Forecast
11.1.4. Regulatory Bodies and Translational Consortia
11.1.4.1. Market Revenue and Volume Forecast
11.1.5. Instrument and Reagent Suppliers (internal R&D use)
11.1.5.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.1.2. Market Revenue and Volume Forecast, by Modality/Approach
12.1.3. Market Revenue and Volume Forecast, by Product and Service Type
12.1.4. Market Revenue and Volume Forecast, by End User
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.1.5.2. Market Revenue and Volume Forecast, by Modality/Approach
12.1.5.3. Market Revenue and Volume Forecast, by Product and Service Type
12.1.5.4. Market Revenue and Volume Forecast, by End User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.1.6.2. Market Revenue and Volume Forecast, by Modality/Approach
12.1.6.3. Market Revenue and Volume Forecast, by Product and Service Type
12.1.6.4. Market Revenue and Volume Forecast, by End User
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.2.2. Market Revenue and Volume Forecast, by Modality/Approach
12.2.3. Market Revenue and Volume Forecast, by Product and Service Type
12.2.4. Market Revenue and Volume Forecast, by End User
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.2.5.2. Market Revenue and Volume Forecast, by Modality/Approach
12.2.5.3. Market Revenue and Volume Forecast, by Product and Service Type
12.2.5.4. Market Revenue and Volume Forecast, by End User
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.2.6.2. Market Revenue and Volume Forecast, by Modality/Approach
12.2.6.3. Market Revenue and Volume Forecast, by Product and Service Type
12.2.6.4. Market Revenue and Volume Forecast, by End User
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.2.7.2. Market Revenue and Volume Forecast, by Modality/Approach
12.2.7.3. Market Revenue and Volume Forecast, by Product and Service Type
12.2.7.4. Market Revenue and Volume Forecast, by End User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.2.8.2. Market Revenue and Volume Forecast, by Modality/Approach
12.2.8.3. Market Revenue and Volume Forecast, by Product and Service Type
12.2.8.4. Market Revenue and Volume Forecast, by End User
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.3.2. Market Revenue and Volume Forecast, by Modality/Approach
12.3.3. Market Revenue and Volume Forecast, by Product and Service Type
12.3.4. Market Revenue and Volume Forecast, by End User
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.3.5.2. Market Revenue and Volume Forecast, by Modality/Approach
12.3.5.3. Market Revenue and Volume Forecast, by Product and Service Type
12.3.5.4. Market Revenue and Volume Forecast, by End User
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.3.6.2. Market Revenue and Volume Forecast, by Modality/Approach
12.3.6.3. Market Revenue and Volume Forecast, by Product and Service Type
12.3.6.4. Market Revenue and Volume Forecast, by End User
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.3.7.2. Market Revenue and Volume Forecast, by Modality/Approach
12.3.7.3. Market Revenue and Volume Forecast, by Product and Service Type
12.3.7.4. Market Revenue and Volume Forecast, by End User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.3.8.2. Market Revenue and Volume Forecast, by Modality/Approach
12.3.8.3. Market Revenue and Volume Forecast, by Product and Service Type
12.3.8.4. Market Revenue and Volume Forecast, by End User
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.4.2. Market Revenue and Volume Forecast, by Modality/Approach
12.4.3. Market Revenue and Volume Forecast, by Product and Service Type
12.4.4. Market Revenue and Volume Forecast, by End User
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.4.5.2. Market Revenue and Volume Forecast, by Modality/Approach
12.4.5.3. Market Revenue and Volume Forecast, by Product and Service Type
12.4.5.4. Market Revenue and Volume Forecast, by End User
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.4.6.2. Market Revenue and Volume Forecast, by Modality/Approach
12.4.6.3. Market Revenue and Volume Forecast, by Product and Service Type
12.4.6.4. Market Revenue and Volume Forecast, by End User
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.4.7.2. Market Revenue and Volume Forecast, by Modality/Approach
12.4.7.3. Market Revenue and Volume Forecast, by Product and Service Type
12.4.7.4. Market Revenue and Volume Forecast, by End User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.4.8.2. Market Revenue and Volume Forecast, by Modality/Approach
12.4.8.3. Market Revenue and Volume Forecast, by Product and Service Type
12.4.8.4. Market Revenue and Volume Forecast, by End User
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.5.2. Market Revenue and Volume Forecast, by Modality/Approach
12.5.3. Market Revenue and Volume Forecast, by Product and Service Type
12.5.4. Market Revenue and Volume Forecast, by End User
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.5.5.2. Market Revenue and Volume Forecast, by Modality/Approach
12.5.5.3. Market Revenue and Volume Forecast, by Product and Service Type
12.5.5.4. Market Revenue and Volume Forecast, by End User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Assay/Test Type
12.5.6.2. Market Revenue and Volume Forecast, by Modality/Approach
12.5.6.3. Market Revenue and Volume Forecast, by Product and Service Type
12.5.6.4. Market Revenue and Volume Forecast, by End User
13.1. Eurofins Scientific
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Certara
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Sophion Bioscience
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Axol Bioscience,
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Thermo Fisher Scientific,
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Multi-Channel Systems (MCS),
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Nanion Technologies,
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Sophion Bioscience
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Evotec
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. WuXi AppTec
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client